›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:CancerNext-Expanded®
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Konica MinoltaType:
Laboratory Developed Test
Related tests:
CancerNext-Expanded is a next generation sequencing panel that simultaneously analyzes 77 genes associated with increased risks for brain, breast, colon, ovarian, pancreatic, prostate, renal, uterine, and many other cancers. Testing should be considered when there are multiple primary tumors in one person that are suspicious for a combination of hereditary breast, ovarian, colorectal, uterine cancers and/or melanoma in addition to hereditary brain tumors, kidney cancer, and/or PGL/PCC.
Cancer:
Breast Cancer, Colon Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Uterine Cancer
Gene:
ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), ATM (ATM serine/threonine kinase), BAP1 (BRCA1 Associated Protein 1), BARD1 (BRCA1 Associated RING Domain 1), BLM (BLM RecQ Like Helicase)
See More ...
ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), ATM (ATM serine/threonine kinase), BAP1 (BRCA1 Associated Protein 1), BARD1 (BRCA1 Associated RING Domain 1), BLM (BLM RecQ Like Helicase), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1), CDH1 (Cadherin 1), CDK4 (Cyclin-dependent kinase 4), CDKN1B (Cyclin dependent kinase inhibitor 1B), CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), CHEK2 (Checkpoint kinase 2), CTNNA1 (Catenin Alpha 1), DICER1 (Dicer 1 Ribonuclease III), EGFR (Epidermal growth factor receptor), EPCAM (Epithelial cell adhesion molecule), FANCC (FA Complementation Group C), FH (Fumarate Hydratase), FLCN (Folliculin), HOXB13 (Homeobox B13), KIT (KIT proto-oncogene, receptor tyrosine kinase), LZTR1 (Leucine Zipper Like Transcription Regulator 1), MET (MET proto-oncogene, receptor tyrosine kinase), MITF (Melanocyte Inducing Transcription Factor), MLH1 (MutL homolog 1), MSH2 (MutS Homolog 2), MSH3 (MutS Homolog 3), MSH6 (MutS homolog 6), MUTYH (MutY homolog), NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)), NF1 (Neurofibromin 1), NF2 (Neurofibromin 2), PALB2 (Partner and localizer of BRCA2), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PMS2 (PMS1 protein homolog 2), POLD1 (DNA Polymerase Delta 1), POLE (DNA Polymerase Epsilon), POT1 (Protection of telomeres 1), PTCH1 (Patched 1), PTEN (Phosphatase and tensin homolog), RAD51C (RAD51 paralog C), RAD51D (RAD51 paralog D), RB1 (RB Transcriptional Corepressor 1), RECQL (RecQ Like Helicase), RET (Ret Proto-Oncogene), SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B), SDHC (Succinate Dehydrogenase Complex Subunit C), SMAD4 (SMAD family member 4), SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4), SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1), STK11 (Serine/threonine kinase 11), SUFU (SUFU Negative Regulator Of Hedgehog Signaling), TMEM127 (Transmembrane Protein 127), TP53 (Tumor protein P53), TSC1 (TSC complex subunit 1), TSC2 (TSC complex subunit 2), VHL (von Hippel-Lindau tumor suppressor), XRCC2 (X-Ray Repair Cross Complementing 2)
Method:
Next-Generation Sequencing (NGS)
